Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review

Executive Summary

EMA and payers want to know more about daily life improvements from US FDA-approved Duchenne muscular dystrophy treatment.

You may also be interested in...



Sarepta Winning Payer War Over Duchenne Muscular Dystrophy Drug Coverage

Exondys 51 has been met with recommendations for restrictions by many insurers, but after consultations with experts and Sarepta execs coverage is expanding.

Keeping Track: US FDA Approves Emflaza And Parsabiv, Turns Down Opioid/Anti-Emetic Combo CL-108

The latest drug development news and highlights from our FDA Performance Tracker.

Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?

Steroid treatment like Emflaza is considered standard of care and availability of other products may make payer discussions difficult.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119810

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel